Saturday 17 October 2026
Export SCNX’s income statement to Excel — free account
Scienture Holdings, Inc.
SCNX Healthcare Pharmaceutical Retailers
Scienture Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $431,600.00, up 216.0% from fiscal 2024. In the quarter to June 2026, revenue grew 3,235.9%, EPS grew 85.4%, free cash flow fell 54.0% and total debt rose 831.4%, each against the same quarter a year earlier.
3.36
0.02
−0.59%
Follow SCNX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
560.77 | 403.62 | 593.65 | 422.06 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(125.36) | (37.81) | (99.24) | (110.67) | |
P/B ratio |
4.87 | 2.79 | 4.34 | 5.41 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
563.21 | 394.23 | 590.71 | 424.39 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(36.41) | (14.28) | (21.60) | (24.14) | |
EV/FCF |
(29.58) | (11.99) | (18.12) | (20.50) | |
Quick Ratio |
0.13 | 2.70 | 1.52 | 2.83 | |
Current Ratio |
0.19 | 2.89 | 1.70 | 3.04 | |
Net Debt/EBITDA |
(0.07) | 0.23 | 1.16 | (0.64) | |
Debt/Assets |
0.51% | 0.00% | 0.00% | 10.91% | |
Debt/Equity |
0.01 | 0.00 | 0.00 | 0.15 | |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF/Net income |
0.89 | 0.18 | 0.86 | 1.11 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(2.42) | (30.87) | (94.85) | (10.01) | |
Research and Development Expense of Revenue |
28.69% | (218.55%) | 1,410.30% | 339.52% | |
Selling, General and Administrative Expense of Revenue |
409.61% | (1,110.79%) | 2,655.24% | 227.07% | |
Intangible Assets out of Total Assets |
0.93 | 0.84 | 0.87 | 0.80 | |
Share Based Compensation of Revenue |
355.84% | (198.64%) | 181.71% | 30.12% | |
Graham Net Nets |
(0.05) | (0.03) | (0.03) | (0.04) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(76.03%) | (21.65%) | (35.20%) | (24.00%) | |
Free Cash Flow Yield |
(3.40%) | (8.15%) | (5.49%) | (4.91%) | |
Revenue per Share |
0.03 | (0.01) | 0.00 | 0.01 | |
Operating CF per Share |
(0.17) | (0.34) | (0.07) | (0.08) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.17) | (0.34) | (0.07) | (0.08) | |
Cash per Share |
0.02 | 0.43 | 0.09 | 0.21 | |
Shareholders Equity per Share |
4.36 | 4.57 | 1.64 | 1.62 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.36 | 4.57 | 1.64 | 1.62 | |
Free Cash Flow |
(3.21) | (5.18) | (2.92) | (3.13) | |
Working Capital |
(5.93) | 5.18 | 1.97 | 6.18 | |
Net Current Asset Value |
(20.74) | (6.14) | (9.07) | (14.43) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.42 | 2.62 | 2.44 | 2.22 | |
Average Payables |
3.29 | 2.17 | 2.29 | 2.03 | |
Average Inventory |
0.12 | 0.11 | 0.11 | 0.11 | |
Average Assets |
99.55 | 94.52 | 93.51 | 96.01 | |
Average Common Equity |
83.90 | 74.60 | 73.99 | 70.98 |
Columns are period end dates